Fig. 3From: The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trialCough frequency and severity (Day 4): Changes from baseline and differences to placebo (Bayesian analyses). Error bars represent 90% credible limits. Placebo data were pooled across the four placebo ‘dose’ steps. Lower VAS scores indicate less severe cough. Total number of patients = 23Back to article page